Dengpiao Xie1, Jianting Wang2, Xinping Wu1, Mingquan Li3. 1. Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. 2. People's Hospital of Fujian Province, Fuzhou, Fujian, China. 3. The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. 3511725549@qq.com.
Abstract
BACKGROUND: The efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemic patients with chronic kidney disease. METHODS: We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemic patients with CKD. RESULTS: Four studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96-1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45-0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07-13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD - 76.1 μg/L; 95% CI - 91.8 to - 60.3, p < 0.00001) and ferritin (WMD - 63.6 μg/L; 95% CI - 96.6 to - 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups. CONCLUSION: Daprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemic patients with chronic kidney disease in the future.
BACKGROUND: The efficacy of daprodustat for the treatment of anemicpatients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemicpatients with chronic kidney disease. METHODS: We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemicpatients with CKD. RESULTS: Four studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96-1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45-0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07-13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD - 76.1 μg/L; 95% CI - 91.8 to - 60.3, p < 0.00001) and ferritin (WMD - 63.6 μg/L; 95% CI - 96.6 to - 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups. CONCLUSION:Daprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemicpatients with chronic kidney disease in the future.
Authors: Francesco Locatelli; Allen R Nissenson; Brendan J Barrett; Rowan G Walker; David C Wheeler; Kai U Eckardt; Norbert H Lameire; Garabed Eknoyan Journal: Kidney Int Date: 2008-07-02 Impact factor: 10.612
Authors: Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein Journal: J Am Coll Cardiol Date: 2002-06-05 Impact factor: 24.094
Authors: William M McClellan; W Dana Flanders; Robert D Langston; Claudine Jurkovitz; Rodney Presley Journal: J Am Soc Nephrol Date: 2002-07 Impact factor: 10.121
Authors: Louis Holdstock; Amy M Meadowcroft; Rayma Maier; Brendan M Johnson; Delyth Jones; Anjay Rastogi; Steven Zeig; John J Lepore; Alexander R Cobitz Journal: J Am Soc Nephrol Date: 2015-10-22 Impact factor: 10.121
Authors: Zhangning Fu; Xiaodong Geng; Kun Chi; Chengcheng Song; Di Wu; Chao Liu; Quan Hong Journal: Front Pharmacol Date: 2022-03-10 Impact factor: 5.810